Top Markets
#1 Black Phoenix Black Phoenix +198.17%
#2 Islamic Coin Islamic Coin +158.02%
#3 Glidr Glidr +84.34%
#4 BasedHype BasedHype +38.64%
#5 Gold Park Gold Park +37.95%
#6 Acurast Acurast +29.31%
#7 Cryptopia Cryptopia +21.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +15.50%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +13.63%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Clasificación en acciones #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$4.94K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Arno Therapeutics, Inc. (ARNI)

Categoría

Healthcare
Ingresos de Arno Therapeutics, Inc. (ARNI)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Arno Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Arno Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE